Does Testosterone Affect Women's Libido? What Research Shows

Sexual desire in women is a complex, biological and psychological phenomenon. It is shaped by an interplay of endocrine function, neurochemistry, psychological well-being, relationship dynamics, and overall physical health. When a woman experiences a persistent or distressing decline in sexual desire, it can affect quality of life, intimate relationships, and personal vitality. In contemporary discussions around female hormonal health, attention has increasingly turned toward testosterone—a hormone traditionally associated with male physiology, but one that performs natural functions within the female body as well. Many women and clinicians ask whether reduced testosterone levels play a key role in low female libido and what evidence-based solutions exist.

At EOS Health, we approach female sexual wellness with warmth, clinical rigor, and complete empathy. Experiencing shifts in sexual desire is a widespread concern that can occur at any stage of life—whether during young adulthood, perimenopause, natural menopause, or periods of intense life stress. Understanding the biological mechanisms of female androgen production, reviewing current clinical research, and recognizing why thorough medical evaluation comes first empowers individuals to make informed decisions alongside licensed healthcare providers.

1. Understanding Testosterone's Natural Role in Female Physiology

Although testosterone is commonly categorized as an androgen or "male sex hormone," women naturally produce and utilize testosterone throughout their lives. In females, testosterone is synthesized primarily by the ovaries and the adrenal glands, with peripheral conversion occurring in adipose tissue and skin. In healthy premenopausal women, the ovaries and adrenal glands produce testosterone in substantial quantities. Before menopause, women produce more testosterone by weight than they do estrogen, although circulating blood concentrations of testosterone remain significantly lower in females than in males.

Within the female body, testosterone acts through specific androgen receptors distributed across multiple tissue types. It contributes to vital physiological functions beyond reproduction and sexuality, including:

• Musculoskeletal and Bone Integrity: Testosterone works with estrogen to stimulate osteoblast activity, helping to maintain bone mineral density and support skeletal strength. It also aids in maintaining lean muscle tissue.
• Central Nervous System and Neurochemistry: Androgen receptors are concentrated in brain regions responsible for mood regulation, cognitive processing, motivation, and energy levels, influencing dopaminergic signaling pathways.
• Vascular and Metabolic Health: Endothelial cells express androgen receptors, where testosterone participates in vasodilation, microvascular circulation, and metabolic balance.
• Pelvic Tissue and Sexual Response: Receptors exist in pelvic structures, including the clitoris, labia, vagina, and pelvic floor vasculature, helping maintain tissue elasticity, lubrication response, and sensory responsiveness.

Free vs. Bound Testosterone and Lab Testing Nuances

To understand testosterone's biological activity, it is helpful to examine how the hormone circulates in the bloodstream. The vast majority of circulating testosterone in women—approximately 98% to 99%—is bound to plasma proteins. Specifically, roughly 66% is tightly bound to Sex Hormone-Binding Globulin (SHBG), while about 32% is loosely bound to albumin. Only a tiny fraction, typically 1% to 2%, remains unbound as "free" testosterone.

Because free testosterone is the bioavailable fraction capable of entering cells and activating androgen receptors, measuring free testosterone often provides a clearer picture than total testosterone alone. Furthermore, SHBG levels fluctuate based on various factors. For instance, oral contraceptives containing estrogen stimulate hepatic SHBG production, reducing free testosterone availability. Conversely, conditions like insulin resistance or hypothyroidism can alter SHBG levels. Additionally, standard automated immunoassay blood tests designed for male testosterone levels often lack sensitivity at the lower physiological ranges typical of women. In clinical research, Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) is considered the standard for measuring female testosterone concentrations accurately.

Hormonal Shifts Across the Lifespan

Unlike estrogen, which experiences a sharp decline during the menopausal transition, female testosterone levels undergo a gradual, age-related reduction. This decline typically begins in a woman's late twenties or early thirties. By the time a woman reaches her late forties, her serum androgen levels may be roughly half of what they were in her early twenties. Furthermore, women who undergo surgical menopause—specifically bilateral oophorectomy (removal of both ovaries)—experience an immediate loss of approximately 50% of their circulating testosterone, frequently resulting in more sudden shifts in sexual desire and physical energy.

2. What Clinical Research Reveals About Testosterone and Female Desire

The relationship between female androgen levels and sexual desire has been extensively investigated over recent decades. Clinical research demonstrates that while testosterone plays a supporting role in sexual motivation and central arousal mechanisms, sexual desire in women cannot be reduced to a single hormonal value. Human sexual desire operates under the "Dual Control Model," where central excitatory mechanisms (mediated by dopamine, norepinephrine, and testosterone) continually interact with inhibitory mechanisms (mediated by serotonin and stress hormones like cortisol).

Global Consensus Findings on Testosterone Therapy

An international consensus panel representing leading medical societies—including the International Menopause Society, the Endocrine Society, ACOG, and the North American Menopause Society—conducted a comprehensive systematic review of clinical trials regarding testosterone therapy in women. Their findings established important clinical principles:

• Efficacy in Postmenopausal HSDD: Multiple randomized, double-blind, placebo-controlled clinical trials demonstrate that physiological testosterone administration can lead to statistically significant improvements in sexual desire, arousal, orgasmic function, and overall sexual satisfaction in postmenopausal women diagnosed with Hypoactive Sexual Desire Disorder (HSDD). Participants frequently experienced a measurable increase in satisfying sexual events compared to placebo groups.
• Physiological Dosing Focus: Benefits were observed strictly when testosterone was administered at physiological doses designed to replicate the normal blood levels of healthy premenopausal women. Supraphysiological doses—such as those formulated for male hypogonadism—are inappropriate for women and significantly increase the risk of adverse side effects.
• Limited Evidence for Premenopausal Women: The consensus panel emphasized that current high-quality evidence remains insufficient to routinely recommend testosterone therapy for low desire in premenopausal women, reinforcing the need for individualized clinical evaluation.
• Lack of Direct Correlation in Baseline Labs: Studies show that baseline circulating testosterone levels do not reliably predict which women will experience low libido or who will respond to therapy. A woman with low serum testosterone may experience normal sexual desire, while another with average levels may experience persistent low desire. Consequently, low testosterone alone does not define a clinical diagnosis.

3. Why Comprehensive Clinical Testing and Diagnostic Evaluation Come First

Because sexual desire is influenced by biological, psychiatric, and environmental variables, a thorough clinical evaluation is an indispensable first step before considering any hormonal or non-hormonal intervention. Self-diagnosing or consuming unmonitored over-the-counter androgen supplements can be unsafe and counterproductive.

Key Diagnostic Steps in a Professional Evaluation

A comprehensive clinical assessment by a licensed healthcare provider typically encompasses the following diagnostic components:

1. Medical and Sexual History: A structured conversation exploring the timeline of desire changes, distress levels, relationship context, sleep patterns, and lifestyle factors.
2. Targeted Laboratory Diagnostics: Reordering comprehensive blood panels to evaluate thyroid function (TSH, free T3, free T4), prolactin, complete blood count (CBC), metabolic markers, fasting glucose, and vitamin D, alongside total and free testosterone, SHBG, and estradiol. Identifying underlying hypothyroidism, hyperprolactinemia, or severe anemia is crucial, as these conditions frequently manifest as fatigue and low libido.
3. Medication and Substance Review: Reviewing all prescription and over-the-counter medications. Certain widely prescribed drugs are known to inhibit sexual desire and arousal:
   • SSRIs and SNRIs: Antidepressants like sertraline, fluoxetine, or venlafaxine increase central serotonergic tone, which can inhibit dopaminergic sexual excitation pathways.
   • Oral Contraceptives: Combination birth control pills elevate hepatic SHBG synthesis, lowering bioavailable free testosterone.
   • Spironolactone and Antiandrogens: Prescribed for acne or hirsutism, these agents block androgen receptors directly.
4. Assessment of Psychological and Relational Factors: Chronic psychological stress triggers Hypothalamic-Pituitary-Adrenal (HPA) axis activation, releasing cortisol, which suppresses central gonadal hormone signaling. Anxiety, depression, body image concerns, history of trauma, fatigue, and relationship dissatisfaction represent major non-hormonal contributors to low desire.
5. Evaluation of Physical Comfort: Screening for genitourinary symptoms of menopause (GSM), vulvovaginal atrophy, dyspareunia (painful intercourse), or pelvic floor dysfunction. When intercourse causes pain or discomfort, decreased desire is often a natural protective response.

4. Exploring Recognizing Conditions and Evidence-Based Therapeutic Options

When low sexual desire is chronic (lasting six months or longer), causes marked distress or interpersonal strain, and is not better explained by another medical condition, it may be formally diagnosed as Hypoactive Sexual Desire Disorder (HSDD). HSDD is a recognized medical condition, and acknowledging it helps demystify the experience and removes unnecessary shame.

Non-Hormonal Evidence-Based Medical Approaches

For women seeking evidence-based therapies for low desire, non-hormonal medical options exist alongside hormonal considerations:

• FDA-Approved Bremelanotide (Vyleesi): Bremelanotide is an FDA-approved prescription medication specifically indicated for the treatment of generalized, hypoactive sexual desire disorder (HSDD) in premenopausal women. As a central melanocortin receptor agonist, bremelanotide activates MC3 and MC4 receptors in the central nervous system, helping to modulate neural pathways involved in sexual motivation and response. It is administered as a subcutaneous injection prior to anticipated sexual activity.
• Compounded PT-141 Formulations: Subcutaneous or nasal spray formulations containing PT-141 utilize the exact same active peptide ingredient as bremelanotide. However, it is essential for patients to understand that compounded medications themselves are custom-prepared by licensed compounding pharmacies and are not FDA-approved. Clinicians carefully evaluate patient safety, medical history, and potential contraindications before considering compounded options.
• Psychological and Psychosexual Therapies: Cognitive Behavioral Therapy (CBT), mindfulness-based cognitive therapy, and specialized sex therapy have demonstrated strong clinical effectiveness. These approaches assist individuals and couples in addressing performance anxiety, improving intimate communication, managing stress, and re-engaging sexual interest.

Safety and Monitoring in Testosterone Therapy

In cases where a licensed healthcare provider determines that physiological testosterone therapy is medically indicated for a postmenopausal patient diagnosed with HSDD, treatment must be closely supervised. Because no FDA-approved female-specific testosterone formulation currently exists in the United States, clinicians may utilize low-dose off-label formulations or custom-compounded creams formulated specifically to achieve female physiological target ranges.

Proper monitoring is critical to prevent androgenic side effects associated with excessive hormone levels, such as acne, hirsutism (excess body or facial hair growth), androgenetic alopecia (scalp hair thinning), voice deepening, or adverse alterations in lipid profiles. Regular clinical follow-ups and blood testing help ensure safety and efficacy throughout care.

5. Partnering with a Licensed Telehealth Clinician for Personalized Care

Addressing shifts in sexual desire requires a compassionate healthcare environment where you feel heard and supported. Modern telehealth platforms have transformed how individuals access specialized reproductive and hormonal healthcare, providing a confidential, convenient, and empowering experience from home.

Through a structured telehealth evaluation, you can complete medical questionnaires, consult with experienced clinicians specializing in female sexual health, obtain diagnostic lab orders at local facilities, and receive personalized care plans. Whether your clinical path involves lifestyle modifications, non-hormonal therapies, or comprehensive endocrine management, working with a licensed clinician ensures your care is tailored to your unique biological profile and personal health goals.

If persistent changes in sexual desire are impacting your well-being, take the initiative to explore personalized options in a supportive medical setting. Visit EOS Health Women's Sexual Health Care to learn more about clinician-guided evaluations and start your personalized wellness journey today.

Hypoactive Sexual Desire Disorder (HSDD)

A medical diagnosis characterized by a chronic lack of sexual desire or interest that causes personal distress and is not accounted for by another health condition or relationship conflict.

Free Testosterone

The small fraction (typically 1–2%) of circulating testosterone that is not bound to plasma proteins like SHBG or albumin, making it bioavailable to enter tissues and bind androgen receptors.

Sex Hormone-Binding Globulin (SHBG)

A protein produced by the liver that binds tightly to sex hormones, regulating the proportion of active, free hormones circulating in the bloodstream.

Bremelanotide

An FDA-approved central melanocortin receptor agonist prescribed for the treatment of generalized HSDD in premenopausal women (marketed under the brand name Vyleesi).

Physiological Dosing

Medication dosing designed to replicate normal, healthy hormonal concentrations naturally found in the body, rather than exceeding normal physiological levels.